Hereditary Angioedema Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Hereditary Angioedema Market is Segmented by Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Other Drug Classes), Route of Administration (Intravenous, Subcutaneous Injection, and Oral), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Report Also Covers the Estimated Market Sizes and Trends for 17 Countries Across Major Regions Globally. The market provides the value (in USD million) for the above-mentioned segments.

Hereditary Angioedema Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Hereditary Angioedema Industry Overview

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies currently dominating the market are CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., BioCryst Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals Inc., and Adverum Biotechnologies Inc.

Hereditary Angioedema Market Leaders

  1. CSL Behring

  2. Takeda Pharmaceutical Company Limited

  3. Pharming Healthcare Inc.

  4. Sanofi

  5. BioCryst Pharmaceuticals Inc.

  6. *Disclaimer: Major Players sorted in no particular order
CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., Sanofi, BioCryst Pharmaceuticals Inc.

Hereditary Angioedema Treatment Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?